Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides a source of glucose for cellular metabolism, primarily via glycolysis and the Krebs cycle, to produce ATP. Sodium chloride maintains fluid and electrolyte balance, acting as a source of sodium and chloride ions essential for osmotic pressure and acid-base homeostasis.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Fluid and electrolyte replacement in patients with hypotonic dehydration,Maintenance of hydration and electrolyte balance,Provision of calories in patients requiring parenteral nutrition
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion: 100-200 m L/hour per 70 kg adult; rate adjusted based on fluid and electrolyte needs, typically 0.5-4 m L/kg/hour.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Not applicable; dextrose and electrolytes are endogenous substances, not subject to classic elimination half-life. Plasma glucose half-life is ~15-20 minutes in euglycemic conditions due to rapid cellular uptake.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Dextrose undergoes cellular metabolism via glycolysis and the Krebs cycle; sodium and chloride are renally excreted and regulated by the kidneys.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Dextrose: primarily metabolized to CO2 and water; <1% excreted unchanged renally. Sodium chloride: electrolytes are reabsorbed or excreted renally; no specific elimination pathway.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
None (0%): dextrose and sodium chloride are not bound to plasma proteins.
Low protein binding; 0–11% bound, primarily to albumin.
Dextrose: Vd ~0.2 L/kg (limited to extracellular fluid); sodium distributes primarily in extracellular fluid (Vd ~0.15-0.3 L/kg).
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100% (complete bioavailability). Not applicable for other routes.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
GFR <30 m L/min: Reduce infusion rate by 50-75% and monitor serum sodium; avoid in anuria.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
Child-Pugh Class B or C: No specific dose adjustment required; monitor for fluid overload and hyponatremia.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Intravenous infusion: 0.5-4 m L/kg/hour, adjusted based on maintenance fluid requirements (e.g., 4-2-1 rule) and clinical status.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Start at lower end of infusion rate (e.g., 0.5-1 m L/kg/hour) due to decreased renal function and higher risk of fluid overload; monitor serum sodium and volume status.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
None.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Monitor serum glucose, electrolytes, and fluid balance regularly,Risk of hyperglycemia in diabetic patients,Volume overload in patients with heart failure or renal impairment,Extravasation risk during IV administration,May cause electrolyte imbalances with prolonged use
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hyperglycemia or glucose intolerance,Hypernatremia or hyperchloremia,Severe renal impairment with oliguria,Severe dehydration (avoid hypotonic solutions in shock),Known allergy to any component
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No direct food interactions with this IV solution. However, oral intake may affect electrolyte balance; patients on sodium restriction should avoid high-sodium foods.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Dextrose and sodium chloride at these concentrations are generally not teratogenic. Glucose is a physiologic nutrient and sodium chloride is an electrolyte; no fetal risks are reported when used appropriately. Trimester risk: Category C (not shown to be harmful, but no controlled studies).
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Compatible with breastfeeding. Dextrose and sodium chloride are normal blood constituents. M/P ratio not applicable; both compounds transfer into breast milk in negligible amounts without adverse effects.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy increases plasma volume, possibly requiring higher volumes of IV fluids. Pharmacokinetic changes: increased GFR may affect electrolyte excretion; dose adjustments are not typically needed but individualize based on maternal hydration status and serum glucose/electrolytes.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
This solution provides 85 m Eq/L sodium and 77 m Eq/L chloride. Use with caution in patients with heart failure, renal impairment, or hypertension due to sodium load. Monitor serum electrolytes and fluid balance. Not for peripheral administration if osmolarity >900 m Osm/L (this solution is isotonic). Assess injection site for phlebitis or extravasation.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This intravenous solution provides fluids and electrolytes, not food calories.,Report any signs of fluid overload: swelling, shortness of breath, or rapid weight gain.,Inform your healthcare provider if you have high blood pressure, heart problems, or kidney issues.,Tell your nurse immediately if you experience pain, redness, or swelling at the IV site.,This solution contains sodium; follow any dietary sodium restrictions as advised by your doctor.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose provides a source of glucose for cellular metabolism, primarily via glycolysis and the Krebs cycle, to produce ATP. Sodium chloride maintains fluid and electrolyte balance, acting as a source of sodium and chloride ions essential for osmotic pressure and acid-base homeostasis.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is: Intravenous infusion: 100-200 m L/hour per 70 kg adult; rate adjusted based on fluid and electrolyte needs, typically 0.5-4 m L/kg/hour.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose and sodium chloride at these concentrations are generally not teratogenic. Glucose is a physiologic nutrient and sodium chloride is an electrolyte; no fetal risks are repo. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.